CA2792771A1 - Injectable drug delivery system - Google Patents

Injectable drug delivery system Download PDF

Info

Publication number
CA2792771A1
CA2792771A1 CA2792771A CA2792771A CA2792771A1 CA 2792771 A1 CA2792771 A1 CA 2792771A1 CA 2792771 A CA2792771 A CA 2792771A CA 2792771 A CA2792771 A CA 2792771A CA 2792771 A1 CA2792771 A1 CA 2792771A1
Authority
CA
Canada
Prior art keywords
formulation
polysaccharide
solvent system
api
glucopyranose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2792771A
Other languages
English (en)
French (fr)
Inventor
Timothy M. Kloke
Joram Slager
Laxma Gundlapally Reddy
David E. Babcock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics Inc
Original Assignee
Surmodics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surmodics Inc filed Critical Surmodics Inc
Publication of CA2792771A1 publication Critical patent/CA2792771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
CA2792771A 2010-03-12 2011-03-11 Injectable drug delivery system Abandoned CA2792771A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31366610P 2010-03-12 2010-03-12
US61/313,666 2010-03-12
PCT/US2011/028195 WO2011112996A2 (en) 2010-03-12 2011-03-11 Injectable drug delivery system

Publications (1)

Publication Number Publication Date
CA2792771A1 true CA2792771A1 (en) 2011-09-15

Family

ID=44148866

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2792771A Abandoned CA2792771A1 (en) 2010-03-12 2011-03-11 Injectable drug delivery system

Country Status (5)

Country Link
US (1) US20110229457A1 (enExample)
EP (1) EP2544658A2 (enExample)
JP (1) JP2013522239A (enExample)
CA (1) CA2792771A1 (enExample)
WO (1) WO2011112996A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613413A1 (en) * 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
AU2013355043A1 (en) * 2012-12-06 2015-07-02 Tobira Therapeutics, Inc. Oligonucleotide formulation
CN106573133B (zh) 2014-08-19 2020-03-03 加利福尼亚大学董事会 用于局部药物递送的植入物及其使用方法
US20180371158A1 (en) * 2015-12-18 2018-12-27 Abraham Joy Peptidomimetic polymers as controlled release matrices for small molecules, biologicals, synthetic or semi-synthetic macromolecules
JP7054793B2 (ja) * 2017-07-07 2022-04-15 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP6952279B2 (ja) * 2017-07-07 2021-10-20 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP7054792B2 (ja) * 2017-07-07 2022-04-15 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
CN110537098B (zh) * 2017-07-07 2022-01-25 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
JP6924969B2 (ja) * 2017-07-07 2021-08-25 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP7487220B2 (ja) * 2019-03-05 2024-05-20 ダウ グローバル テクノロジーズ エルエルシー カスパーゼ活性を誘導するためのポリエチレングリコール誘導体
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN111956638B (zh) * 2020-08-06 2023-01-24 上海宛文创业孵化器管理合伙企业(有限合伙) 蓓萨罗丁或/和其药学上可接受的盐在制备抗肺动脉高压药物中的应用
WO2023056447A1 (en) 2021-10-01 2023-04-06 Promega Corporation Compounds and methods for detection of nitric oxide
CN116870238A (zh) * 2023-08-25 2023-10-13 中国海洋大学 一种抑菌介孔淀粉止血粉及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433101A1 (de) * 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6472512B1 (en) * 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
EP1481695A1 (en) * 1999-10-15 2004-12-01 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US6703040B2 (en) 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
CA2494241C (en) * 2000-02-08 2011-06-14 Allergan, Inc. Botulinum toxin pharmaceutical compositions
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
JP4817088B2 (ja) * 2000-10-10 2011-11-16 株式会社林原生物化学研究所 塞栓材料
IL159048A0 (en) * 2001-06-21 2004-05-12 Genentech Inc Sustained release formulation
JP4624678B2 (ja) * 2002-02-21 2011-02-02 パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド 架橋生物活性ヒドロゲルマトリックス
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
DE102004021240B4 (de) * 2004-04-30 2008-07-31 Infineon Technologies Ag Verfahren zur Herstellung einer Halbleiter-Schaltungsanordnung in BiCMOS-Technologie
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
US20090092650A1 (en) * 2004-12-15 2009-04-09 Warren Stephen L Sustained Delivery Formulations of Octreotide Compounds
CA2645324A1 (en) 2006-03-15 2007-09-27 Surmodics, Inc. Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
WO2010141553A1 (en) * 2009-06-02 2010-12-09 Surmodics, Inc. SILANE-FUNCTIONALIZED HYDROPHOBIC a(1→4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION

Also Published As

Publication number Publication date
JP2013522239A (ja) 2013-06-13
WO2011112996A2 (en) 2011-09-15
US20110229457A1 (en) 2011-09-22
EP2544658A2 (en) 2013-01-16
WO2011112996A3 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
US20110229457A1 (en) Injectable drug delivery system
Tsung et al. Biodegradable polymer-based drug-delivery systems for ocular diseases
Gu et al. Hydrogels with smart systems for delivery of hydrophobic drugs
EP2906246B1 (en) Vegf neutralizing prodrugs comprising ranibizumab for the treatment of ocular conditions characterized by ocular neovascularization
Bader et al. Polysialic acid-based micelles for encapsulation of hydrophobic drugs
US9364545B2 (en) Thermosensitive injectable hydrogel for drug delivery
EP1393718A1 (en) Colloidal drug carrier system
EP3711748B1 (en) Hydrogel composition for drug delivery and uses thereof
CN113164616A (zh) 可降解的透明质酸水凝胶
JP2008534747A (ja) Ｐｅｇ−ポリアセタールグラフトコポリマーおよびｐｅｇ−ポリアセタール−ｐｏｅグラフトコポリマーならびに医薬組成物
CN1194002C (zh) 短链化多核苷酸及其制备方法
WO2014179615A2 (en) Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
JP5987132B2 (ja) 生医学的使用のためのビタミンで機能化したゲル形成ブロック・コポリマー
CN107106596A (zh) 喜树碱类高分子衍生物的药物制剂
US8697105B2 (en) Injectable drug delivery formulation
KR20180014042A (ko) 약물을 전달하기 위한 가교된 히알루론산 및 이를 이용한 약학적 제제
CN104784105A (zh) 一种单克隆抗体药物的凝胶组合物
CA3238759A1 (en) Extruded ocular inserts or implants and methods thereof
US20200375891A1 (en) Bioerodible cross-linked hydrogel implants and related methods of use
JP2008537757A (ja) Ｐｅｇ−ポリ（オルトエステル）グラフトコポリマーおよび医薬組成物
JP2015505551A (ja) 点眼用抗体含有徐放性製剤
CN107921040A (zh) 含有喜树碱类高分子衍生物的药物组合物
Alwiswasi et al. Ophthalmic Single and Mixed Polymeric Nanomicelles using Brimonidine as a model drug: Preparation, Characterization, and Physical Properties Evaluation
US20220125930A1 (en) System and method for fabrication of large, porous drug-silk materials using cryogranulation
WO2025097049A1 (en) Rna-sn-38 conjugate for the treatment of colorectal cancer and sequential lung metastasis

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160311